Faraday Pharmaceuticals Inc.

Cardiovascular Medicine

Clinical research is centered on anterior ST-elevation myocardial infarction, with attention to acute myocardial infarction care and outcomes following percutaneous coronary intervention.

  • Acute coronary syndromes
  • STEMI management
  • Reperfusion therapy

The therapeutic focus includes reducing cardiovascular mortality and limiting the development of heart failure after a major ischemic cardiac event.

Heart Failure Prevention

Research activity also extends to post-infarction complications, particularly the prevention of heart failure events in patients recovering from a large anterior myocardial infarction.

  • Post-infarction remodeling
  • Left ventricular dysfunction
  • Cardiac event reduction

The clinical emphasis is on preserving cardiac function after ischemic injury and addressing early complications linked to poor long-term prognosis.

Acute Hospital Cardiology

The sponsor’s trial portfolio involves inpatient treatment settings for patients with acute myocardial infarction, reflecting interest in urgent cardiovascular care pathways and immediate post-event management.

  • Emergency cardiac care
  • Coronary revascularization
  • In-hospital outcomes

This area of research aligns with strategies that address the most critical period following coronary artery occlusion.

Multicenter Cardiovascular Trials

Clinical development is carried out across a broad network of collaborating sites in multiple countries, supporting research in cardiovascular therapeutics for patients with ST-elevation myocardial infarction.

  • International site collaboration
  • Cardiac clinical research networks
  • Global enrollment in cardiology

The sponsor’s active interest is concentrated on advancing treatment options for severe ischemic heart disease in diverse clinical settings.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

    Not recruiting

    3 1
    Investigated drugs:
    Czechia Germany Hungary Italy The Netherlands Poland +3